Stock LBT LBT INNOVATIONS LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Financials LBT Innovations Limited

Equities

LBT

AU000000LBT8

Biotechnology & Medical Research

Market Closed - Australian S.E.
Other stock markets
 12:02:47 2024-04-30 am EDT 		5-day change 1st Jan Change
0.02 AUD -4.76% Intraday chart for LBT Innovations Limited -.--% +81.82%
Apr. 29 LBT Innovations Sells APAS Independence Instrument to NovaCina MT
Mar. 13 Australian Shares Track Gains of Wall Street Peers as Market Shrugs Off US Inflation Data MT

Valuation

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Capitalization 1 23.11 27.06 54.17 21.97 24.95 10.37
Enterprise Value (EV) 1 15.53 19.39 50.95 17.22 26.45 11.74
P/E ratio -6.76 x -5.35 x -9.61 x -3 x -3.58 x -0.44 x
Yield - - - - - -
Capitalization / Revenue 3.88 x 10.6 x - 628 x 11.7 x 4.87 x
EV / Revenue 2.61 x 7.59 x - 492 x 12.4 x 5.51 x
EV / EBITDA -4.8 x -4.92 x -8.75 x -2.6 x -3.37 x -1.65 x
EV / FCF -10.2 x -6.01 x -37 x -6.57 x -6.2 x 7.97 x
FCF Yield -9.84% -16.6% -2.7% -15.2% -16.1% 12.5%
Price to Book 0.79 x 0.92 x 2.25 x 0.88 x 1.17 x -99 x
Nbr of stocks (in thousands) 200,927 235,340 235,540 289,115 319,902 345,796
Reference price 2 0.1150 0.1150 0.2300 0.0760 0.0780 0.0300
Announcement Date 9/27/18 8/29/19 8/27/20 8/26/21 8/29/22 9/29/23
1AUD in Million2AUD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net sales 1 5.958 2.553 - 0.035 2.128 2.132
EBITDA 1 -3.235 -3.939 -5.824 -6.612 -7.847 -7.096
EBIT 1 -3.274 -3.983 -5.881 -6.658 -7.9 -7.141
Operating Margin -54.95% -156.01% - -19,022.86% -371.24% -334.94%
Earnings before Tax (EBT) 1 -4.301 -5.994 -7.415 -9.504 -8.759 -20.88
Net income 1 -2.685 -4.35 -5.636 -7.26 -6.641 -22.52
Net margin -45.07% -170.39% - -20,742.86% -312.08% -1,056.47%
EPS 2 -0.0170 -0.0215 -0.0239 -0.0253 -0.0218 -0.0683
Free Cash Flow 1 -1.529 -3.225 -1.378 -2.621 -4.266 1.473
FCF margin -25.67% -126.33% - -7,487.86% -200.45% 69.09%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 9/27/18 8/29/19 8/27/20 8/26/21 8/29/22 9/29/23
1AUD in Million2AUD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2018 2019 2020 2021 2022 2023
Net Debt 1 - - - - 1.5 1.37
Net Cash position 1 7.57 7.68 3.22 4.76 - -
Leverage (Debt/EBITDA) - - - - -0.191 x -0.1926 x
Free Cash Flow 1 -1.53 -3.23 -1.38 -2.62 -4.27 1.47
ROE (net income / shareholders' equity) -10.6% -14.8% -21% -29.6% -28.7% -212%
ROA (Net income/ Total Assets) -6.15% -6.71% -10.2% -12% -14.7% -23%
Assets 1 43.68 64.86 55.12 60.59 45.2 98.14
Book Value Per Share 2 0.1400 0.1300 0.1000 0.0900 0.0700 -0
Cash Flow per Share 2 0.0400 0.0400 0.0300 0.0300 0.0100 0.0100
Capex 1 0.07 0.04 0.04 0.07 0.05 0.01
Capex / Sales 1.14% 1.68% - 208.57% 2.3% 0.28%
Announcement Date 9/27/18 8/29/19 8/27/20 8/26/21 8/29/22 9/29/23
1AUD in Million2AUD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
LBT INNOVATIONS LIMITED Stock LBT Innovations Limited
+81.82% 18.45M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+0.17% 42.86B
MODERNA, INC. Stock Moderna, Inc.
+10.92% 42.74B
LONZA GROUP AG Stock Lonza Group AG
+44.30% 41.36B
CELLTRION, INC. Stock Celltrion, Inc.
-6.20% 27.68B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+5.23% 25.15B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-24.79% 18.63B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.69% 12.37B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.13% 11.92B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.57% 11.21B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. LBT Stock
  4. Financials LBT Innovations Limited